| P/E (FY) | 0.2 | Sales (TTM) | $7.4M |
| Earnings (TTM) | $163.6M | ROE | — |
| Net Margin | 2848.63% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | −64.23% |
| Market Cap | $28.2M | Trading Days | 128 |
| 52W High | 9.70 |
| 52W Low | 6.32 |
| % Off High | −28.09% |
Europe 88% · JP 12%
| Ann. Volatility (1Y) | 50.78% | Ann. Volatility (3Y) | 50.78% |
| Sharpe (1Y) | −0.95 | Sharpe (3Y) | −0.95 |
| Max Drawdown (1Y) | −32.00% | Max Drawdown (3Y) | −32.00% |
| YTD | −26.58% | Since inception | −26.58% |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| ABVC | ABVC BIOPHARMA, INC. | $27.6M | — |
| FBLG | FibroBiologics, Inc. | $29.0M | — |
| ATNM | Actinium Pharmaceuticals, Inc. | $27.2M | — |
| LTRN | Lantern Pharma Inc. | $29.4M | — |
| BCTX | BriaCell Therapeutics Corp. | $30.2M | — |
| BTAI | BioXcel Therapeutics, Inc. | $26.1M | — |
| IGC | IGC Pharma, Inc. | $25.9M | — |
| SER | Serina Therapeutics, Inc. | $31.0M | — |
| ACTU | ACTUATE THERAPEUTICS, INC. | $25.4M | — |
| PVCT | PROVECTUS BIOPHARMACEUTICALS, INC. | $25.2M | — |
| LITS | Lite Strategy, Inc. |
| $33.0M |
| — |
| TXMD | TherapeuticsMD, Inc. | $23.8M | — |
